Skip to content
10-K

Annual Report

BioRestorative Therapies, Inc. BRTX

0001493152-26-012925

← back to feed
Filed
Mar 26, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 23, 2026 25.48M sh
Shares Diluted FY 2025 · Dec 31, 2025 8.99M sh
Shares Diluted FY 2025 · Dec 31, 2024 7.76M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $0
Capex FY 2025 · Dec 31, 2025 $116.07K
Capex FY 2025 · Dec 31, 2024 $106.19K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$10.79M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$8.23M
Cash And Equivalents FY 2025 · Dec 31, 2025 $1.51M
Cash And Equivalents FY 2025 · Dec 31, 2024 $547.89K
Stockholders Equity FY 2025 · Dec 31, 2025 $356.74K
Stockholders Equity FY 2025 · Dec 31, 2024 $8.53M
Current Liabilities FY 2025 · Dec 31, 2025 $3.72M
Current Liabilities FY 2025 · Dec 31, 2024 $3.75M
Current Assets FY 2025 · Dec 31, 2025 $3.14M
Current Assets FY 2025 · Dec 31, 2024 $11.14M
Total Assets FY 2025 · Dec 31, 2025 $4.08M
Total Assets FY 2025 · Dec 31, 2024 $12.28M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.58
Eps Diluted FY 2025 · Dec 31, 2024 −$1.16
Eps Basic FY 2025 · Dec 31, 2025 −$1.58
Eps Basic FY 2025 · Dec 31, 2024 −$1.16
Sga Expense FY 2025 · Dec 31, 2025 $5.89M
Sga Expense restated FY 2025 · Dec 31, 2024 $5.22M
Rd Expense FY 2025 · Dec 31, 2025 $10.09M
Rd Expense restated FY 2025 · Dec 31, 2024 $6.71M
Net Income FY 2025 · Dec 31, 2025 −$14.24M
Net Income FY 2025 · Dec 31, 2024 −$8.98M
Operating Income FY 2025 · Dec 31, 2025 −$15.65M
Operating Income FY 2025 · Dec 31, 2024 −$11.56M
Gross Profit FY 2025 · Dec 31, 2025 $335.86K
Gross Profit FY 2025 · Dec 31, 2024 $372.93K
Cost Of Revenue FY 2025 · Dec 31, 2025 $23.84K
Cost Of Revenue FY 2025 · Dec 31, 2024 $28.07K
Revenue FY 2025 · Dec 31, 2025 $359.7K
Revenue FY 2025 · Dec 31, 2024 $401K
Stock Issued FY 2025 · Oct 8, 2025 678.13K sh